Literature DB >> 17531849

Cerebrospinal fluid analysis in multiple sclerosis.

Francisco A Luque1, Stephen L Jaffe.   

Abstract

Although the diagnosis of multiple sclerosis (MS) may be clinically suspect and the magnetic resonance imaging findings compatible, cerebrospinal fluid (CSF) analysis remains mandatory in order to support the diagnosis. This is especially important since our understanding of the defining disease pathogenesis remains incomplete. However, there is no specifically diagnostic CSF test. And until recently, laboratory techniques for CSF analysis had not been rigorously standardized. Unconcentrated CSF without fixative should be used for the determinations of cell count and differential, protein and glucose, lactate, myelin basic protein, and the CSF/serum albumin ratio which is an indicator of blood-CSF barrier disruption. Additionally, CSF immunoglobulin-gamma (IgG) determinations are of major importance and are now included in the MS diagnostic criteria. Testing for oligoclonal IgG bands utilizing isoelectric focusing with IgG immunoblotting, the IgG synthesis rate, and the IgG index should be included. CSF analysis for kappa light chains and IGM may be diagnostically helpful. The search for biomarkers including those possibly present in the CSF which could predict and assess the course as well as response to treatment in a particular MS patient has not yet been successful. CSF immunoglobulin and T-cell/B-cell patterns, soluble HLA class I and II antigens, nitrous oxide metabolites, neurofilament and microtubule components and antibodies, tau protein, 14-3-3-protein, neuronal cell and intercellular adhesion molecules, and chemokines are actively being investigated as MS biomarkers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531849     DOI: 10.1016/S0074-7742(07)79015-3

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  9 in total

1.  Theiler's virus infection: Pathophysiology of demyelination and neurodegeneration.

Authors:  Fumitaka Sato; Hiroki Tanaka; Faris Hasanovic; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2011-02

2.  Serum Glial Fibrillary Acidic Protein: A Surrogate Marker of the Activity of Multiple Sclerosis.

Authors:  Inas K Sharquie; Gheyath Al Gawwam; Shatha F Abdullah
Journal:  Medeni Med J       Date:  2020-09-30

Review 3.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

4.  The role of infections in the pathogenesis and course of multiple sclerosis.

Authors:  Siddharama Pawate; Subramaniam Sriram
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

5.  Disease-modifying therapies in relapsing-remitting multiple sclerosis.

Authors:  Fabricio González-Andrade; José Luis Alcaraz-Alvarez
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

6.  Mechanisms and pharmacology of neuropathic pain in multiple sclerosis.

Authors:  T Iannitti; B J Kerr; B K Taylor
Journal:  Curr Top Behav Neurosci       Date:  2014

7.  A fast and reproducible method for albumin isolation and depletion from serum and cerebrospinal fluid.

Authors:  Ronald J Holewinski; Zhicheng Jin; Matthew J Powell; Matthew D Maust; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2013-01-29       Impact factor: 3.984

8.  Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance.

Authors:  Feliciana Real-Fernández; Irene Passalacqua; Elisa Peroni; Mario Chelli; Francesco Lolli; Anna Maria Papini; Paolo Rovero
Journal:  Sensors (Basel)       Date:  2012-05-02       Impact factor: 3.576

9.  The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis.

Authors:  Cecilia Smith Simonsen; Heidi Øyen Flemmen; Trine Lauritzen; Pål Berg-Hansen; Stine Marit Moen; Elisabeth Gulowsen Celius
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.